Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988634 · ClinicalTrials.gov registry record · Phase 3
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
A Phase 3 study of Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 467
- Enrollment target
- 20
- Study locations
NCT03988634 is a Phase 3 study of Heart Failure With Preserved Ejection Fraction (HFPEF) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 467 participants, above the 168-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (178% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT03988634, a Phase 3 study of Heart Failure With Preserved Ejection Fraction (HFPEF), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 467 participants
- Enrollment target
- 20
- Study locations
Study Summary
The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days post-decompensation.
Conditions Studied
Interventions
- DRUG sacubitril/valsartan
- DRUG valsartan
- DRUG sacubitril/valsartan matching placebo
- DRUG valsartan matching placebo
Study Locations (20)
California
- University of Calif Irvine Med Cntr - Irvine
- Memorial Care Health System Memorialcare Long Beach - Long Beach
- University Of Southern California . - Los Angeles
- University Of Southern California - Los Angeles
- San Diego Cardiac Center - San Diego
- Zuckerberg General W84 Research . - San Francisco
- Sutter Health Network . - San Pablo
- Helping Hands Medical Associates INC - Santa Ana
Florida
- University of Florida Health . - Gainesville
- New Generation of Medical Research Avera Health N Central Heart - Hialeah
- University of Florida Health Science Center - Jacksonville
- Intercoastal Medical Group - Sarasota
Colorado
- St Francis Medical Center - Colorado Springs
- Colorado Heart and Vascular . - Lakewood
- South Denver Cardiology Associates PC - Littleton
Connecticut
- Hartford Healthcare Headache Center - West Hartford
- VA Connecticut Healthcare System - West Haven
Georgia
- Morehouse School Of Medicine - Atlanta
- Emory University School of Medicine/Winship Cancer Institute - Atlanta
Delaware
- Cardiology Physicians PA . - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2019-06-29 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03988634
The ClinicalTrials.gov registry entry for NCT03988634 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 168-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (178% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction (HFPEF) appearing as the primary indexed condition, and to 4 interventions - of which sacubitril/valsartan is the first listed.
NCT03988634 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT03988634 about?
NCT03988634 is a clinical study titled "Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)". The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days post-decompensation.
What is the current status of trial NCT03988634?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 467 participants. The study started on 2019-06-29. Estimated completion is 2022-12-14.
What conditions does trial NCT03988634 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction (HFPEF).
What interventions are being tested in trial NCT03988634?
The interventions under investigation include: sacubitril/valsartan (DRUG), valsartan (DRUG), sacubitril/valsartan matching placebo (DRUG), valsartan matching placebo (DRUG).
Who is sponsoring clinical trial NCT03988634?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03988634 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction (HFPEF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
RECRUITING
-
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 1
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
RECRUITING
-
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
RECRUITING
-
Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.